Company intelligence / Profile preview

Neowise Biotechnology

Ownership: Private
Development stage: Phase 1

Overview

Neowise has advanced several TCR-T cell therapy programs into clinical trials for solid tumors. Positive efficacy and favorable safety profiles have been observed in multiple indications including colorectal, pancreatic, and ovarian cancers. The company’s proprietary CAST® platform enables rapid discovery of high-affinity natural TCRs targeting a wide range of tumor antigens.

Therapeutic areas: Oncology
Modalities: TCR-T cell therapyCell therapyGene therapy (as part of TCR-T platform)
Industry: Biotech

Drug pipeline

5 assets

NW-301D

4 more assets in the full pipeline.

Request access →

Partnerships

BeOne Medicines Ltd. — licensing agreement for use of Neowise’s proprietary antigen-specific TCR molecules to develop iPSC-based off-the-shelf cell therapies.

Beyond the preview

Go deeper on Neowise Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neowise Biotechnology.

Explore the full profile